Načítá se...
Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis
BACKGROUND: Rifapentine has potent activity against Mycobacterium tuberculosis but the optimal dose for tuberculosis treatment is unknown. OBJECTIVE: to determine antimicrobial activity, safety, and tolerability of rifapentine 450 mg or 600 mg administered daily during the first 8 weeks of pulmonary...
Uloženo v:
| Vydáno v: | Int J Tuberc Lung Dis |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6783281/ https://ncbi.nlm.nih.gov/pubmed/26056101 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5588/ijtld.14.0868 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|